B
TRIL

Bailard’s Trillium Therapeutics Inc. TRIL Stock Holding History

Bailard’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-31,000
Closed -$301K – 783
2021
Q2 		$301K Buy
+31,000
New +$292K 0.01% 530

Other funds holding TRIL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Bailard's TRIL Position: Q3 2021 in Review

Bailard sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2021, closing a stake of 31,000 shares — an estimated $301K sold.

Bailard first reported a position in TRIL in Q2 2021 and held it in 1 quarter. The position peaked at $301K in Q2 2021. 181 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

  • Bailard reported no remaining Trillium Therapeutics Inc. position as of Q3 2021 after selling out during the quarter.
  • Bailard sold 31,000 Trillium Therapeutics Inc. shares in Q3 2021, an estimated $301K.
  • Bailard first reported a position in Trillium Therapeutics Inc. in Q2 2021 and held it in 1 quarter.
  • Bailard's Trillium Therapeutics Inc. position peaked at $301K in Q2 2021.
  • 181 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on Bailard's 13F filing for Q3 2021, filed 15 Nov 2021.